NRX PHARMACEUTICALS INC (NRXP) Stock Price, Quote, News and Overview
NASDAQ:NRXP - Nasdaq - US6294442099 - Common Stock - Currency: USD
NRXP Quote, Performance and Key Statistics
NRX PHARMACEUTICALS INC
NASDAQ:NRXP (2/5/2025, 8:17:29 PM)
After market: 2.76 -0.08 (-2.82%)2.84
+0.15 (+5.58%)
The current stock price of NRXP is 2.84 USD. In the past month the price decreased by -19.09%. In the past year, price decreased by -44.53%.
NRXP Latest News, Press Releases and Analysis
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Engage BTIG as Financial Advisor
HOPE has announced plans to assemble a best-in-class global network of interventional psychiatry clinics combining ketamine treatment with transcranial...
Small-Cap NRx Pharma’s Stock Draws Heavy Retail Buzz After Securing $27M Funding
Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold.
What's Going On With NRX Pharmaceuticals Stock Tuesday?
NRX Pharmaceuticals shares are moving higher on Tuesday after it invested $27 million in its subsidiary HOPE Therapeutics.
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition
$25 million investment in HOPE to consist of Series A (non-dilutive to NRx shareholders) convertible into 1/3 of fully diluted HOPE equity, with a 15% current...
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Advances Relationship with Anson Funds with $8.9 Million Financing, Including Above the Market Equity and Senior Secured Debt
/PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx", "NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today...
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Regains Compliance With Nasdaq Minimum Market Value of Listed Securities Requirement
/PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced that on January...
NRXP Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 82.81 | 799.50B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 29.06 | 380.66B | ||
| JNJ | JOHNSON & JOHNSON | 15.48 | 372.43B | ||
| MRK | MERCK & CO. INC. | 11.74 | 226.83B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.62 | 219.98B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.86 | 219.54B | ||
| PFE | PFIZER INC | 8.5 | 149.84B | ||
| SNY | SANOFI-ADR | 13.51 | 134.13B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 51.03 | 121.10B | ||
| ZTS | ZOETIS INC | 30.5 | 79.26B | ||
| GSK | GSK PLC-SPON ADR | 9.11 | 76.92B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.09 | 42.39B |
Related stock screener links
About NRXP
Company Profile
NRX Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Wilmington, Delaware. The company went IPO on 2017-11-20. NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The firm is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The firm has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The firm is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The firm is also engaged in the development of its new product, NRX-102.
Company Info
NRX PHARMACEUTICALS INC
1201 Orange Street, Suite 600
Wilmington DELAWARE US
CEO: Richard Ackerman
Employees: 2
Company Website: https://www.nrxpharma.com/
Investor Relations: https://ir.nrxpharma.com/
Phone: 14842546134
NRXP FAQ
What is the stock price of NRXP?
The current stock price of NRXP is 2.84 USD.
What is the symbol for NRX PHARMACEUTICALS INC stock?
The exchange symbol of NRX PHARMACEUTICALS INC is NRXP and it is listed on the Nasdaq exchange.
On which exchange is NRXP stock listed?
NRXP stock is listed on the Nasdaq exchange.
Is NRXP a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for NRXP, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of NRXP.
Does NRXP stock pay dividends?
NRXP does not pay a dividend.
What is the Price/Earnings (PE) ratio of NRXP?
NRXP does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.04).
What is the Short Interest ratio of NRXP stock?
The outstanding short interest for NRXP is 13.12% of its float.
NRXP Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to NRXP. When comparing the yearly performance of all stocks, NRXP is one of the better performing stocks in the market, outperforming 90.06% of all stocks.
NRXP Financial Highlights
Over the last trailing twelve months NRXP reported a non-GAAP Earnings per Share(EPS) of -2.04. The EPS decreased by 60% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -456.95% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NRXP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to NRXP. The Buy consensus is the average rating of analysts ratings from 9 analysts.